Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults

This will be a multi-site, randomized, counterbalanced, two-period, two-sequence, validation
study of the online, unsupervised Brain Performance Test (BPT). Over the course of 14 days,
participants will complete two in-clinic visits during which they will complete both the BPT
and in-person neuropsychological assessments (NP).

Inclusion Criteria:

- Native English speaker

- Capable and willing to provide informed consent

- Able to use a computer and mouse without assistance

- Limited (< 3 days) or no experience with Lumosity.com

- Limited (< 3 days) or no experience with other cognitive training programs (e.g.,
FitBrains, CogMed)

- Willing to refrain from online cognitive training during the course of the study

- No recent (<1 years) experience with either computer-based or in-person
neuropsychological tests (e.g., WAIS-IV, WISC, Halstead-Reitan Battery, MATRICS,
CogState, CNS Vital Signs)

- Good general health assessed via self-reported online physical questionnaire and
medical history questionnaire

Exclusion Criteria:

- Illiterate or unable to understand written English sufficiently to comprehend study
instructions and consent form

- Uncorrected visual impairment (beyond that required to qualify for a California
Driver's License) that may impact the ability to complete assessments (self-report or
determined by the clinician)

- Uncorrected auditory impairment that may impact the ability to complete assessments
(self-report or determined by the clinician)

- Self-reported clinical diagnosis for primary psychiatric or neurological disorder
(e.g., schizophrenia, multiple sclerosis, attention deficit hyperactivity disorder,
Parkinson's disease, epilepsy)

- Self-reported history of concussion or traumatic brain injury, that is considered
clinically significant in the opinion of the investigator (e.g. loss of consciousness
≤ 30 minutes)

- Self-reported diagnosis of mental retardation or pervasive developmental disorder

- Self-reported diagnosis of Mild Cognitive Impairment, Alzheimer's disease, or other
dementia

- Self-reported history of sustained substance or alcohol abuse or dependence, that is
considered clinically significant in the opinion of the investigator (e.g. as defined
by DSM-5)

- Self-report that subject is currently taking an antipsychotic, antidepressant,
anti-anxiety, or a cognitively-enhancing medication (e.g. Ritalin), or in the last 72
hours, narcotics for pain or other medications that may impact cognitive performance
(e.g. sleeping medications/aides or cold/allergy medications)

- Any other significant medical condition that could impact cognitive performance or
result in cognitive impairment in the opinion of the investigator

- Score <28 on the MMSE

- Positive urine test for recent substance use on either testing day

- Breath Alcohol Content of 0.01% or greater on either testing day